Newsroom

What's happening
across the portfolio

Milestones, clinical progress, and corporate updates from CinRx and our CinCos.
  1. CinRx Pharma

    Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease

    Graviton BioScience and CinRx Pharma form CinRock Pharma to advance ROCK2-targeted therapies for cardiovascular disease.

    Read story
  2. CinDome Pharma

    CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

    CinDome announced the completion of patient enrollment in its envisionGI Phase 2 clinical study evaluating deudomperidone (CIN-102) for the treatment of idiopathic gastroparesis.

    Read story
  3. CinDome Pharma

    CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

    CinDome announced enrollment completion in its envision3D Phase 2 trial evaluating deudomperidone (CIN-102) for the treatment of diabetic gastroparesis.

    Read story
  4. CinDome Pharma

    CinDome Pharma Announces First Patient Dosed in Clinical Trial of Deudomperidone (CIN-102)

    CinDome announced the dosing of the first patient in its clinical trial of deudomperidone (CIN-102) for the treatment of idiopathic gastroparesis.

    Read story
  5. CinRx Pharma

    CinRx Pharma Announces Additional $73 Million Financing

    CinRx Pharma announced an additional $73 million financing to further capitalize its portfolio of asset-focused subsidiary companies and accelerate clinical execution across multiple programs.

    Read story
Showing 5 of 13
Connect

Let's advance medicine, together

Whether you're a clinical investigator, a potential partner, or considering joining our team - we'd like to hear from you.